ClinicalTrials.gg
TerminatedNCT06419634Updated Oct 1, 2026

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase 1 interventional study of BMS-986497 and Azacitidine in Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Bristol-Myers Squibb. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Inability to meet protocol objectives
Updated Oct 1, 2026Now TerminatedNo longer in France+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb — 1 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid, Acute · Bristol-Myers Squibb.

Enrollment
17th of 30
34 · median 38
Started
2024
the only one that year
Phase 1
16 of 43
none open now
Registered
41st of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 17th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2024, is one of 16 in phase 1, and was the 41st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

1 of the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Keywords

  • BMS-986497
  • First-in-Human
  • ORM-6151
  • Acute myeloid leukemia (AML)
  • Myelodysplastic syndrome (MDS)
  • Cluster of differentiation 33 (CD33)
  • G1 to S phase transition 1 (GSPT1)
  • Open label study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with primary or secondary acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • Detectable levels of cluster of differentiation 33 (CD33) expression.
  • Failed alternative therapies with established benefit.
  • (ECOG) performance status ≤2 and adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Acute Promyelocytic Leukemia.
  • Clinically active central nervous system leukemia.
  • Active malignant solid tumor.
  • Pregnant or breastfeeding.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation BMS-986497 (Monotherapy)

    Drug: BMS-986497

  • Experimental
    Part 2, Cohort A: Dose Expansion BMS-986497 (Combination Therapy)

    Drug: BMS-986497 · Drug: Azacitidine

  • Experimental
    Part 2, Cohort B: Dose Expansion BMS-986497 (Triple Combination Therapy)

    Drug: BMS-986497 · Drug: Azacitidine · Drug: Venetoclax

Interventions

  • DrugBMS-986497

    Specified dose on specified days

    Also known as: ORM-6151

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Time frame: Up to 21 days

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 years

  3. Determine the Recommended Phase 2 Dose (RP2D) of BMS-986497 as Monotherapy

    Time frame: Up to 2 years

  4. RP2D of BMS-986497 as Combination Therapy

    The combination therapy included BMS-986497 and Azacitidine

    Time frame: Up to 2 years

  5. RP2D of BMS-986497 as Triple Combination Therapy

    The triple combination therapy included BMS-986497, Azacitidine and Venetoclax.

    Time frame: Up to 2 years

Secondary outcomes

  1. Maximum concentration (Cmax)

    Time frame: Up to 2 years

  2. Time to reach Cmax (Tmax)

    Time frame: Up to 2 years

  3. Area under the curve from time 0 to last quantifiable concentration (AUC0-last)

    Time frame: Up to 2 years

  4. Overall response rate (ORR)

    Time frame: Up to 4 years

  5. Duration of response (DoR)

    Time frame: Up to 4 years

  6. Best overall response (BOR)

    Time frame: Up to 4 years

  7. Complete remission (CR)

    Time frame: Up to 4 years

  8. Complete remission with incomplete hematologic recovery (Cri)

    Time frame: Up to 4 years

  9. Complete remission with partial hematologic recovery (CRh) rate

    Time frame: Up to 4 years

  10. Event-free survival (EFS)

    Time frame: Up to 4 years

  11. Transition rate to allogeneic hematopoietic stem cell transplantation (HSCT)

    Time frame: Up to 4 years

  12. Incidence of Anti-drug antibody (ADA) against BMS-986497

    Time frame: Up to 2 years

07

Study locations

10 sites
  • Local Institution - 0011
    New Haven, Connecticut 06510, United States
  • Local Institution - 0010
    Chicago, Illinois 60611, United States
  • Local Institution - 0014
    Boston, Massachusetts 02114, United States
  • Local Institution - 0013
    St Louis, Missouri 63108, United States
  • Local Institution - 0008
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0006
    Houston, Texas 77030, United States
  • Local Institution - 0002
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0003
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0020
    Barcelona, Catalunya [Cataluña] 08036, Spain
  • Local Institution - 0023
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Aug 2026, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Feb 2027 → Aug 2026 and completion Sep 2030 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 17, 2024
StartActual
May 29, 2024
Primary completionActual
Aug 28, 2026was Feb 2027
CompletionActual
Aug 28, 2026was Sep 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Inability to meet protocol objectives
changed Oct 1, 2026
Sites
10 sites added, 16 sites removed; no longer in France
Show 10 added (6 United States, 2 Canada, 2 Spain)
  • Local Institution - 0011 · New Haven, United States
  • Local Institution - 0010 · Chicago, United States
  • Local Institution - 0014 · Boston, United States
  • Local Institution - 0013 · St Louis, United States
  • Local Institution - 0008 · Hackensack, United States
  • Local Institution - 0006 · Houston, United States
  • Local Institution - 0002 · Toronto, Canada
  • Local Institution - 0003 · Montreal, Canada
  • Local Institution - 0020 · Barcelona, Spain
  • Local Institution - 0023 · Seville, Spain
Show 16 removed
  • Yale-New Haven Hospital · New Haven, United States
  • Northwestern Memorial Hospital · Chicago, United States
  • Local Institution - 0007 · Boston, United States
  • Massachusetts General Hospital · Boston, United States
  • Washington University School of Medicine, Siteman Cancer Center · St Louis, United States
  • John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, United States
  • Columbia University Irving Medical Center · New York, United States
  • University of Texas MD Anderson Cancer Center · Houston, United States
  • Local Institution - 0009 · Fairfax, United States
  • Princess Margaret Cancer Centre · Toronto, Canada
  • Jewish General Hospital · Montreal, Canada
  • Local Institution - 0017 · Marseille, France
  • Local Institution - 0018 · Paris, France
  • Local Institution - 0022 · Toulouse, France
  • Hospital Clínic de Barcelona · Barcelona, Spain
  • Hospital Universitario Virgen Del Rocio · Seville, Spain
Oct 1, 2026
Primary completion
Feb 1, 2027→Aug 28, 2026 (actual)
Oct 1, 2026
Study completion
Sep 16, 2030→Aug 28, 2026 (actual)
Oct 1, 2026
Enrollment
105 (estimated)→34 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Terminated
    Why stopped Inability to meet protocol objectives
    10 sites added, 16 sites removed; no longer in France
    Show 10 added (6 United States, 2 Canada, 2 Spain)
    • Local Institution - 0011 · New Haven, United States
    • Local Institution - 0010 · Chicago, United States
    • Local Institution - 0014 · Boston, United States
    • Local Institution - 0013 · St Louis, United States
    • Local Institution - 0008 · Hackensack, United States
    • Local Institution - 0006 · Houston, United States
    • Local Institution - 0002 · Toronto, Canada
    • Local Institution - 0003 · Montreal, Canada
    • Local Institution - 0020 · Barcelona, Spain
    • Local Institution - 0023 · Seville, Spain
    Show 16 removed
    • Yale-New Haven Hospital · New Haven, United States
    • Northwestern Memorial Hospital · Chicago, United States
    • Local Institution - 0007 · Boston, United States
    • Massachusetts General Hospital · Boston, United States
    • Washington University School of Medicine, Siteman Cancer Center · St Louis, United States
    • John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, United States
    • Columbia University Irving Medical Center · New York, United States
    • University of Texas MD Anderson Cancer Center · Houston, United States
    • Local Institution - 0009 · Fairfax, United States
    • Princess Margaret Cancer Centre · Toronto, Canada
    • Jewish General Hospital · Montreal, Canada
    • Local Institution - 0017 · Marseille, France
    • Local Institution - 0018 · Paris, France
    • Local Institution - 0022 · Toulouse, France
    • Hospital Clínic de Barcelona · Barcelona, Spain
    • Hospital Universitario Virgen Del Rocio · Seville, Spain
    Primary completion Feb 1, 2027→Aug 28, 2026 (now actual)
    Study completion Sep 16, 2030→Aug 28, 2026 (now actual)
    Enrollment 105 (estimated)→34 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06419634
Responsible party
Sponsor
First posted
May 17, 2024
Start date
May 29, 2024
Primary completion
Aug 28, 2026
Completion
Aug 28, 2026
Last update
Oct 1, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion